Compare Novavax Inc (NVAX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares UltraPro S&P500 — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while ProShares UltraPro S&P500 trades at $148.04. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | UPRO | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.19 | $157.66 |
52-Week Low | $6.22 | $89.29 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
UPRO trades at $149.32, down 1.69% with neutral technical signals. The stock shows mixed technical indicators with bullish moving averages but neutral oscillators. Recent S&P 500 market discussions highlight AI-driven growth potential alongside concerns about high valuations and geopolitical risks. The stock faces support at $146 and resistance at $151, with overall market sentiment balanced between optimism and caution.
The outlook for UPRO remains tied to broader S&P 500 performance, with potential upside from AI productivity gains but risks from elevated valuations and interest rate uncertainty. Investors face a balanced risk-reward profile with technical support providing near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
